Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites

被引:1911
作者
Paech, K
Webb, P
Kuiper, GGJM
Nilsson, S
Gustafsson, JA
Kushner, PJ
Scanlan, TS
机构
[1] UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143
[4] KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14186 HUDDINGE,SWEDEN
[5] KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN
[6] KARO BIO AB,NOVUM,S-14157 HUDDINGE,SWEDEN
关键词
D O I
10.1126/science.277.5331.1508
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The transactivation properties of the two estrogen receptors, ER alpha and ER beta, were examined with different ligands in the context of an estrogen response element and an AP1 element. ER alpha and ER beta were shown to signal in opposite ways when complexed with the natural hormone estradiol from an AP1 site: with ER alpha, 17 beta-estradiol activated transcription, whereas with ER beta, 17 beta-estradiol inhibited transcription, Moreover, the antiestrogens tamoxifen, raloxifene, and imperial Chemical industries 164384 were potent transcriptional activators with ER beta at an AP1 site. Thus, the two ERs signal in different ways depending on ligand and response element, This suggests that ER alpha and ER beta may play different roles in gene regulation.
引用
收藏
页码:1508 / 1510
页数:3
相关论文
共 22 条
  • [1] RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS
    BLACK, LJ
    SATO, M
    ROWLEY, ER
    MAGEE, DE
    BEKELE, A
    WILLIAMS, DC
    CULLINAN, GJ
    BENDELE, R
    KAUFFMAN, RF
    BENSCH, WR
    FROLIK, CA
    TERMINE, JD
    BRYANT, HU
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) : 63 - 69
  • [2] ACTIVATION OF THE OVALBUMIN GENE BY THE ESTROGEN-RECEPTOR INVOLVES THE FOS-JUN COMPLEX
    GAUB, MP
    BELLARD, M
    SCHEUER, I
    CHAMBON, P
    SASSONECORSI, P
    [J]. CELL, 1990, 63 (06) : 1267 - 1276
  • [3] Tamoxifen: Teaching an old drug new tricks?
    Grainger, DJ
    Metcalfe, JC
    [J]. NATURE MEDICINE, 1996, 2 (04) : 381 - 385
  • [4] GRANDIEN K, UNPUB
  • [5] ANTIESTROGENS .2. STRUCTURE ACTIVITY STUDIES IN A SERIES OF 3-AROYL-2-ARYLBENZO[B]THIOPHENE DERIVATIVES LEADING TO [6-HYDROXY-2-(4-HYDROXYPHENYL)BENZO[B]THIEN-3-YL][4-[2-(1-PIPERIDINYL)ETHOXY]-PHENYL]METHANONE HYDROCHLORIDE (LY156758), A REMARKABLY EFFECTIVE ESTROGEN ANTAGONIST WITH ONLY MINIMAL INTRINSIC ESTROGENICITYO[
    JONES, CD
    JEVNIKAR, MG
    PIKE, AJ
    PETERS, MK
    BLACK, LJ
    THOMPSON, AR
    FALCONE, JF
    CLEMENS, JA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (08) : 1057 - 1066
  • [6] Nuclear hormone receptors: Ligand-activated regulators of transcription and diverse cell responses
    Katzenellenbogen, JA
    Katzenellenbogen, BS
    [J]. CHEMISTRY & BIOLOGY, 1996, 3 (07): : 529 - 536
  • [7] EFFECTS OF TAMOXIFEN ON UTERUS AND OVARIES OF POSTMENOPAUSAL WOMEN IN A RANDOMIZED BREAST-CANCER PREVENTION TRIAL
    KEDAR, RP
    BOURNE, TH
    POWLES, TJ
    COLLINS, WP
    ASHLEY, SE
    COSGROVE, DO
    CAMPBELL, S
    [J]. LANCET, 1994, 343 (8909) : 1318 - 1321
  • [8] Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
    Kuiper, GGJM
    Carlsson, B
    Grandien, K
    Enmark, E
    Haggblad, J
    Nilsson, S
    Gustafsson, JA
    [J]. ENDOCRINOLOGY, 1997, 138 (03) : 863 - 870
  • [9] KULPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925
  • [10] THE RXR HETERODIMERS AND ORPHAN RECEPTORS
    MANGELSDORF, DJ
    EVANS, RM
    [J]. CELL, 1995, 83 (06) : 841 - 850